Thought Field Therapy and Cognitive Therapy for Agoraphobia

Agoraphobia Clinical Trial

Official title:

Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00932919
• Other study ID #: SSHF-70343-AUIR-2
• Status: Completed
• Phase: N/A
• First received: July 3, 2009
• Last updated: April 22, 2014
• Start date: October 2006
• Est. completion date: November 2010

Study information

• Verified date: April 2014
• Source: Sorlandet Hospital HF
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway:National Committee for Medical and Health Research Ethics
• Study type: Interventional

Clinical Trial Summary

The purpose for this study is to find out if Thought field therapy has the same effect as, or better effect than, Cognitive therapy for Agoraphobia.

Description:

Thought field therapy is an alternative treatment method that has shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 72 patients will be randomized to three groups. 24 patients will receive cognitive therapy as a control method, 24 patients will receive thought field therapy. The remaining 24 patients will wait three months, and then be randomized to either of the two therapies.

Before inclusion all patients will be diagnosed with M.I.N.I. and SCID II. They will fill out self evaluation forms for symptoms and quality of life, before and after treatment, and one year after treatment.

All patients will undergo an interview with ADIS on panic and agoraphobic diagnosis and symptoms before starting treatment, and on panic and agoraphobic symptoms immediately after and one year after treatment. These interviews will be done by psychologists who are blinded for which type of treatment the patients have got.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients ages 18 years or older,

• Patients with agoraphobia,

• Patients with a score on Mobility Inventory "Alone" of 2.5 or more,

• Patients who give a written consent to participate.

Exclusion Criteria:

• Psychosis (past or present),

• Drug abuse or dependency,

• Moderate or high score on suicidal behaviour on the M.I.N.I.,

• Patients who have another illness (other than panic disorder or agoraphobia) and are in need of immediate treatment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Agoraphobia

Intervention

Behavioral:
• Thought field therapy
5 sessions with Thought field therapy
• Cognitive therapy
12 sessions of Cognitive therapy
• Wait list
3 months waiting, then randomized to either thought field therapy or cognitive therapy

Locations

Country	Name	City	State
Norway	Sorlandet Hospital	Arendal

Sponsors (1)

Lead Sponsor	Collaborator
Sorlandet Hospital HF

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in agoraphobic situation scores in ADIS.		Immedeately and 12 months after treatment	No
Secondary	Interference score in ADIS		Immediately and 12 months after treatment	No
Secondary	Mobility Inventory		Immediately and 12 months after treatment	No
Secondary	Agoraphobic Cognitions Questionnaire		Immediately and 12 months after treatment	No
Secondary	Body Sensations Questionnaire		Immediately and 12 months after treatment	No
Secondary	BDI		Immediately and 12 months after treatment	Yes
Secondary	BAI		Immediately and 12 months after treatment	No
Secondary	WHOQOL-BREF		Immediately and 12 months after treatment	No
Secondary	SF-36		Immediately and 12 months after treatment	No
Secondary	Safety Seeking Behaviours Questionnaire.		Immediately and 12 months after treatment	No
Secondary	Panic scale		Immediately and 12 months after treatment	No